We are a group of Biopharmaceutical companies
from Europe innovating in Anti-Microbial resistance research

The Challenge

The emergence of multi-drug resistant bacteria presents a global public health crisis which demands the development of new antibiotics, preventive or alternative strategies, yet the R&D investment from large pharmaceutical companies is on the wane due to lack of attractiveness of investment in this therapeutic area.

Innovation is thus largely driven by small and medium biopharma companies, and European nations need to engage more extensively in supporting this innovation via new policies and R&D stimulating incentives.

Our Commitment

The BEAM Alliance will work to improve the regulatory, investment, and commercial environments in Europe for research, development, approval and market viability of new products combating antimicrobial resistance.

Representing

European small and medium biopharmaceutical companies involved in developing innovative products to tackle antimicrobial resistance.

Giving

Members a unique voice to propose and support policies and incentives to identified issues in Europe.

Collaborating

With the existing community of stakeholders dedicated to implementing tangible solutions.

Recommending

Bold incentives that warrant action by policymakers to stimulate innovation by biopharma companies.

Our Members


ABAC Therapeutics

Spain

Abgentis

UK

Absynth Biologics

UK

Adenium Biotech

Denmark

Aicuris

Germany

Alaxia

France

Allecra

Germany

Antabio

France

AntibioTx

Denmark

Arsanis Biosciences

Austria

Auspherix

UK

BioFilm Control

France

Bioversys

Switzerland

Biovertis

Austria

Blueberry Therapeutics

UK

Cantab Anti-infectives

UK

Centauri Therapeutics

UK

Da Volterra

France

Deinobiotics

France

Destiny Pharma

UK

Discuva

UK

Eligo Bioscience

France

Evotec

Germany

FAB Pharma

France

Helperby

UK

IMMT

Slovenia

Immunsystem

Sweden

Lamellar Biomedical

UK

Maat Pharma

France

MGB Biopharma

UK

Micreos

NL

Mutabilis

France

Nabriva Therapeutics

Austria

NAICONS

Italy

Neem Biotech

UK

Northern Antibiotics

Finland

Nosopharm

France

Novabiotics

UK

OLMIX

FR

Pherecydes

France

Phico Therapeutics

UK

Polyphor

Switzerland

Redx Pharma

UK

Septeos

France

Setlance

Italy

Setubio

France

Synamp Pharma

NL

TechnoPhage

Portugal

Vibiosphen

France


Associated Members

BioAster

France

MEDINA Foundation

Spain

TranScrip

UK

Our Actions

April 2015. Presentation of an ePoster at the Pipeline Corner @ECCMID, 25th European Congress of Clinical Microbiology and Infectious Diseases, 25 - 28 April 2015 in Copenhagen. Download the poster here! The Pipeline Corner was mentioned in the press here and here.

30 September 2015. Publication of the Alliance's Position Paper: key measures to reinvigorate antimicrobial research across Europe. The BEAM Alliance urges European and national public authorities to take three key short term actions with immediate effect: (1) create a specific fund dedicated to small and medium biopharmas developing innovative antibacterial products, (2) enhance market incentives to increase the Return on Investment for products tackling antimicrobial resistance through the creation of a special status, (3) simplify regulatory pathways for products tackling antimicrobial resistance.
Download the position paper, the English press release, the French press release.

January 2016. Signature of the Declaration by the Pharmaceutical, Biotechnology and Diagnostics Industries on Combating Antimicrobial Resistance. The BEAM Alliance signed the Declaration by the Pharmaceutical, Biotechnology and Diagnostics Industries on Combating Antimicrobial Resistance that was launched on January 21, 2016. The declaration calls upon governments to work with global pharmaceutical, diagnostics and biotechnology industries to develop new ways to provide sustainable market models for antibiotics and commit the funds needed to implement them. The BEAM Alliance and the other signatories commit themselves to further action in reducing the development of drug resistance, increasing investment in R&D to meet public health needs and to improve access to high-quality antibiotics for all.
Learn more here.

April 2016. Presentation of an ePoster at the Pipeline Corner @ECCMID, 26th European Congress of Clinical Microbiology and Infectious Diseases, April 2016 in Amsterdam. Download the poster here!

May 2016. The BEAM Alliance becomes an associated member to DRIVE-AB!

19 May 2016. The BEAM Alliance The Beam Alliance fully supports Jim O’Neill’s Comprehensive Plan to Combat Superbugs!
Biotech companies such as members of the BEAM Alliance are strongly supportive of the vision and pragmatic solutions proposed by the UK Review on AMR. It is the first time such a thorough global economic analysis on the threat on AMR with long-time projections is published. We, as actors of innovation in the field, face every day the funding needs, path to market and other healthcare payers issues well raised by the Jim O’Neil team, which limit and even sometimes prevent us from translating potential great innovative ideas to products on the market.
The Global Innovation Fund, Market entry and Diagnostic Rewards, the promotion of novel alternative and preventives solutions, and overall better rewards to innovation by National healthcare purchase and distribution systems on AMR solutions, are all ambitious but required actions to radically change the current crisis situation.
We are hopeful that worldwide leaders will not only acknowledge conclusions of this report, but actually decide to join forces and act now to win the battle against resistance to antibiotics. Read the press release and the full report for the action plan.

Get in touch


BEAM Alliance
Da Volterra - Le Dorian B1 - 172 rue de Charonne
75011 PARIS - FRANCE
Email
contact@beam-alliance.eu
We're on social networks